Discovery of ( R )-9-Ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1- a ]isoindol- 6(2 H )-one, a Selective, Orally Active Agonist of the 5-HT _2C Receptor

Citations Over TimeTop 25% of 2007 papers

Abstract

Robust pharmaceutical treatment of obesity has been limited by the undesirable side-effect profile of currently marketed therapies. This paper describes the synthesis and optimization of a new class of pyrazinoisoindolone-containing, selective 5-HT2C agonists as antiobesity agents. Key to optimization of the pyrazinoisoindolone core was the identification of the appropriate substitution pattern and functional groups which led to the discovery of (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one (58), a 5-HT2C agonist with >300-fold functional selectivity over 5-HT2B and >70-fold functional selectivity over 5-HT2A. Oral dosing of 58 reduced food intake in an acute rat feeding model, which could be completely reversed by a selective 5-HT2C antagonist and caused a reduction in body weight gain in a 4-day rat model.

Related Papers

• → LC/MS evaluation of metabolism and membrane transport of bombesin peptides(2010)8 cited
• → Serum Oestradiol Pattern during Coasting is Different in Antagonist Cycles Compared with Long Agonist Cycles in In Vitro Fertilisation(2013)2 cited
• → Use of an antagonist for estimating the degree of agonist stimulation during physiological release(1995)10 cited
• → Swillens replies(1993)1 cited
• → DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION(2018)